Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_14
Snippet: Finally, we combined the PK and PD models as in Fig. 3a to project the percentage of viral replication inhibited over time at different assumed intracellular EC50 values (18, 19) . With high assumed drug potency (EC50=0.8 uM), antiviral effect are sustained over the 10-day dosing interval and are maintained for a long period once drug delivery has stopped (Fig. 3e) . At higher assumed EC50 values, remdesivir potency is projected to be lower......
Document: Finally, we combined the PK and PD models as in Fig. 3a to project the percentage of viral replication inhibited over time at different assumed intracellular EC50 values (18, 19) . With high assumed drug potency (EC50=0.8 uM), antiviral effect are sustained over the 10-day dosing interval and are maintained for a long period once drug delivery has stopped (Fig. 3e) . At higher assumed EC50 values, remdesivir potency is projected to be lower.
Search related documents:
Co phrase search for related documents- antiviral effect and drug potency: 1, 2
- antiviral effect and long period: 1
- antiviral effect and time inhibit: 1
- antiviral effect and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- different time inhibit and time inhibit: 1
- dose interval and PD PK model: 1
- dose interval and viral replication: 1
- drug delivery and viral replication: 1, 2, 3, 4, 5, 6
- drug potency and viral replication: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date